Core Viewpoint - Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 23,200 shares on February 5, indicating a consistent trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the past 5 trading days, southbound funds have reduced their holdings for 5 days, with a total net reduction of 42,900 shares [1] - Over the last 20 trading days, southbound funds have reduced their holdings for all 20 days, resulting in a cumulative net reduction of 188,000 shares [1] - Currently, southbound funds hold 5,681,300 shares of Gaoshi Medical, accounting for 3.83% of the company's total issued ordinary shares [1] Group 2: Company Overview - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates through four segments: proprietary products, distribution, technical services, and other services [1] - The proprietary products segment develops and produces surgical equipment, related software, intraocular lenses, and diagnostic and treatment devices for eye diseases [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | ...

Core Viewpoint - The stock price of Gaoshi Medical (02407) has experienced fluctuations following its removal from the Hong Kong Stock Connect list, with a significant increase of 65.50% from May to September last year, but has since faced a decline of nearly 20% since December 22, raising questions about its upcoming performance in the 2025 annual report [1][2]. Group 1: Stock Performance - After being removed from the Hong Kong Stock Connect list, Gaoshi Medical's stock price initially rose, achieving a monthly "four consecutive increases" [1]. - The stock price saw a cumulative increase of 65.50% from May to September last year, but began a three-month period of sideways movement starting in mid-September [1]. - Since December 22, the stock has declined nearly 20%, effectively reversing all gains made since the mid-year report [1]. Group 2: Market Dynamics - On March 10, the adjustment of the Hong Kong Stock Connect list led to an average stock price drop of 14.24% for the excluded stocks, with Gaoshi Medical being one of them [1]. - Despite the stock's removal, the proportion of shares held by Hong Kong Stock Connect investors has only decreased by 3% over the past 10 months, indicating limited selling pressure [2]. - The liquidity of Gaoshi Medical's stock has noticeably decreased post-removal, with monthly trading volumes dropping by 84.39% from February to April last year [4]. Group 3: Financial Performance - In 2024, Gaoshi Medical reported revenues of 1.428 billion yuan, a year-on-year increase of 1.6%, but net profit fell by 46.75% to 92.394 million yuan due to factors like currency fluctuations and goodwill impairment [7]. - The company has been attempting to adjust its business structure by increasing the proportion of self-owned products, but the revenue from agency products rebounded to 68.55% in 2024 [8]. - In the first half of 2025, Gaoshi Medical achieved revenues of 653 million yuan, a 1.7% increase year-on-year, with a gross profit margin of 48.3%, reflecting an improvement [9]. Group 4: Future Outlook - Analysts project that Gaoshi Medical's revenues will grow to 1.564 billion, 1.715 billion, and 1.875 billion yuan from 2025 to 2027, with corresponding net profits of 135 million, 180 million, and 214 million yuan [9]. - Following the release of the mid-year report, Gaoshi Medical's stock price surged by 19.31% over two days, indicating positive market sentiment towards its performance [9]. - The current trading volume and price movements suggest that the stock may be nearing a bottom, with potential for recovery as market conditions improve [10].

Core Viewpoint - The stock price of Gaoshi Medical (02407) has experienced fluctuations following its removal from the Hong Kong Stock Connect list, with a significant increase in the first half of the year, but a subsequent decline of nearly 20% since December 22, raising questions about its upcoming performance in the 2025 annual report [1][2][7]. Group 1: Stock Performance - Gaoshi Medical's stock price rose by 65.50% from May to September last year, despite being removed from the Hong Kong Stock Connect list in March [1]. - Following a peak, the stock entered a three-month period of consolidation before declining after December [1]. - The stock has seen a cumulative decline of nearly 20% since December 22, effectively reversing all gains made since the mid-year report [1]. Group 2: Hong Kong Stock Connect Impact - On March 10, the adjustment of the Hong Kong Stock Connect list led to an average stock price drop of 14.24% for excluded stocks, with Gaoshi Medical being one of the affected companies [1]. - Despite the stock's removal, the proportion of shares held by Hong Kong Stock Connect investors decreased only slightly from 6.85% to 3.85% over ten months, indicating limited selling pressure [2]. Group 3: Trading Volume and Liquidity - Post-removal, the trading volume of Gaoshi Medical's shares significantly decreased, with a drop of 84.39% in monthly trading volume from February to April compared to the previous period [4]. - By December, the monthly trading volume had further declined to just 97.35 million shares [4]. Group 4: Financial Performance - In 2024, Gaoshi Medical reported revenues of 1.428 billion yuan, a year-on-year increase of 1.6%, but a 4.1% decrease in gross profit to 663 million yuan, with net profit down 46.75% to 92.39 million yuan [7]. - The decline in profitability was attributed to factors such as exchange rate fluctuations and the implementation of national procurement policies for artificial crystals, alongside goodwill impairment totaling 23.26 million yuan [7]. Group 5: Business Strategy and Future Outlook - Gaoshi Medical is attempting to adjust its business structure by increasing the proportion of self-owned products, although the revenue share from distribution products increased to 68.55% in 2024 [8]. - The company reported a significant improvement in its financials for the first half of 2025, with revenues of 653 million yuan, a 1.7% increase, and a net profit of 35.9 million yuan, up 33.5% [8]. - Analysts project revenue growth for 2025-2027, with expected revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, and net profits of 135 million, 180 million, and 214 million yuan respectively [9].

Group 1 - The core point of the article is that southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 900 shares on January 8, 2026, marking a trend of consistent reduction over recent trading days [1] - In the last 5 trading days, southbound funds have reduced their holdings for 5 days, with a total net reduction of 93,600 shares [1] - Over the past 20 trading days, there has been a total net reduction of 220,500 shares, indicating a sustained decrease in holdings [1] Group 2 - As of January 8, 2026, southbound funds hold 5.7582 million shares of Gaoshi Medical, which represents 3.88% of the company's total issued ordinary shares [1] - The shareholding changes over the last few trading days show a slight decline, with a maximum reduction of 72,200 shares on December 30, 2025, which corresponds to a 1.23% decrease [2] - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables, operating through four segments [2]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 本月底法定/ ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 2,800 shares on December 22, with a total net reduction of 30,700 shares over the last five trading days and 155,200 shares over the last twenty trading days [1] - As of now, southbound funds hold 5,852,700 shares of Gaoshi Medical, which represents 3.95% of the company's total issued ordinary shares [1] Group 2 - Gaoshi Medical Technology Co., Ltd. primarily engages in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates through four segments: proprietary products, distribution, technical services, and others [1] - The proprietary products segment develops and produces surgical equipment and related software, intraocular lenses, diagnostic and treatment equipment for eye diseases, and related consumables [1] - The distribution segment sells multifunctional diagnostic equipment, fundus diagnostic, surgical, and treatment equipment produced by other ophthalmic medical device manufacturers, along with related consumables [1] - The technical services segment provides warranty services, maintenance services, and consumables used for after-sales services [1] - The other segment mainly includes granting intellectual property rights and providing clinical research organization-related services [1]

Group 1 - The core point of the news is that Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 2,900 shares on December 9, 2025, marking a continuous trend of reduction over the past trading days [1] - In the last 5 trading days, Southbound funds have cumulatively reduced their holdings by 70,500 shares, while in the last 20 trading days, the total reduction amounts to 151,000 shares [1] - As of now, Southbound funds hold 5,908,200 shares of Gaoshi Medical, which represents 3.99% of the company's total issued ordinary shares [1] Group 2 - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [2] - The company operates through four segments: proprietary products, distribution, technical services, and other services, including clinical research organization services [2] - The proprietary products segment develops and produces surgical equipment, related software, intraocular lenses, and diagnostic and treatment equipment for eye diseases [2]

Core Viewpoint - The company, Gaoshi Medical (02407), has announced that its subsidiary, Shenzhen Gaoshi Technology Co., Ltd., has officially obtained ISO13485:2016/EN ISO13485:2016 medical device quality management system certification from DEKRA, which covers the entire process of design, development, production, and sales of its products [1] Group 1: Certification Details - The certification encompasses the eye electrophysiological diagnostic system, corneal contact lens, and phacoemulsification vitreous cutting system collection box [1] - DEKRA, established in 1925, is a globally recognized independent non-listed professional inspection, testing, and certification organization [1] Group 2: Importance of ISO13485 - ISO13485 is a specialized quality management system standard for the medical device industry, focusing on patient-centered risk management and comprehensive quality control throughout the product lifecycle [1] - The certification is recognized by major global medical device regulatory bodies, including China's NMPA, the EU's CE, and the US FDA, serving as a core compliance basis [1] Group 3: Implications for the Company - The acquisition of this important qualification represents a significant achievement in the company's quality management system development [1] - It lays a solid foundation for the company to continuously expand into international markets [1]

Core Viewpoint - The company, GaoShi Medical (02407), has received ISO 13485:2016/EN ISO 13485:2016 certification from DEKRA, indicating compliance with international quality management standards for medical devices [1] Group 1: Certification Details - The certification covers the entire process of design, development, production, and sales of the company's ophthalmic electrophysiological diagnostic systems, corneal contact caps, and phacoemulsification vitreous cutting surgical system collection boxes [1] - DEKRA, established in 1925, is a leading independent non-listed professional inspection, testing, and certification organization with a wide industry coverage [1] Group 2: Importance of ISO 13485 - ISO 13485 is a specialized quality management system standard for the medical device industry, focusing on patient-centered risk management and comprehensive quality control throughout the product lifecycle [1] - The certification is recognized by global medical device regulatory bodies such as China's NMPA, the EU's CE, and the US FDA, ensuring that products meet regulatory requirements and are subject to continuous improvement [1] Group 3: Strategic Implications - The acquisition of this important qualification represents a significant achievement in the company's quality management system development, laying a solid foundation for the company to expand into international markets [1]